Industry TrendsBrand Founders3 min read5 January 2026

Peptides Are Having a Moment. Here's What Beauty Brands Actually Need to Know.

Peptide-led skincare is projected to hit $8.2bn by 2028. But most brands are getting the formulation story wrong.

SL
Sophie Lansbury

Beauty 2.0 Founder - 20 years in the beauty industry

Pick one hero peptide, explain exactly what it does for skin, and own that story - multi-peptide complexity is a marketing crutch, not a differentiator.

Key takeaway

In brief
What beauty brands actually need to know about the peptide boom - formulation strategy, consumer education, and how to stand out in a crowded market.
Who this is for
Brand Founders
Main takeaway
Pick one hero peptide, explain exactly what it does for skin, and own that story - multi-peptide complexity is a marketing crutch, not a differentiator.
What to do next
Audit your current peptide narrative and test whether a customer can explain your hero ingredient after one page visit.

The peptide boom is real - and messy

Every other brand launching in 2026 seems to have peptides as a hero ingredient. Matrixyl, Argireline, copper peptides, signal peptides - the language is everywhere. And for good reason: consumer search volume for "peptide skincare" is up 340% year-on-year.

But here's what most brands are getting wrong: they're treating peptides like a checkbox. Throw in three peptides, slap "multi-peptide complex" on the label, and call it innovation.

That's not innovation. That's ingredient stuffing. And consumers are getting smarter.

What consumers actually want

The shift we're seeing across our client base is this: consumers don't want more ingredients. They want clearer stories about fewer ingredients.

They want to understand what one peptide does and why it matters for their specific concern. Not a laundry list of five peptides with no explanation of how they work together.

The brands winning right now are the ones that:

  • Pick one hero peptide and build the entire product narrative around it
  • Explain the mechanism of action in plain language (not in clinical jargon)
  • Show before-and-after evidence or clinical trial results
  • Position the peptide within a routine context, not in isolation

The formulation challenge brands underestimate

Peptide stability is genuinely difficult. Copper peptides degrade in the wrong pH environment. Signal peptides need specific delivery systems to actually penetrate. Most contract manufacturers will happily formulate a "peptide serum" at concentrations too low to have any meaningful effect, and you'll never know unless you ask the right questions.

Questions to ask your formulator:

  • What is the minimum effective concentration for this peptide, and are we at or above it?
  • What is the stability profile across our target shelf life?
  • How does this peptide interact with the other active ingredients in the formula?
  • Is there clinical evidence for this specific peptide at this concentration?

If your formulator can't answer these clearly, that's a red flag.

The regulatory angle

Claims around peptides are getting tighter. The EU Commission has been increasingly scrutinising "botox-like" and "anti-wrinkle" claims linked to peptide products. If you're positioning a topical peptide as a replacement for injectables - even implicitly - you need robust evidence or you're exposed.

Safe positioning: focus on skin texture, firmness, and hydration benefits. Avoid any comparison to medical procedures, even casually in marketing copy.

What this means for your brand

If you're formulating with peptides, be honest with yourself about whether you're leading with science or with buzzwords. The market is saturated enough that "contains peptides" is no longer a differentiator. The differentiator is clarity: one peptide, one story, one proof point.

The brands that will still be winning in 2027 are the ones investing in the science now, not just the label claims.

Share
SL

Sophie Lansbury

Founder of Beauty 2.0. Nearly 20 years in beauty — from counter to boardroom, indie launches to global houses. Writes about the operational reality of growing beauty brands.

About Sophie

The brands winning with peptides aren't the ones with the longest INCI list. They're the ones telling the clearest story about one hero peptide and what it does.

Was this helpful?

Related posts

ONE MANUFACTURER, TWO CONTRACTSTHE FACTORYSTOCK FORMULASOLD ON TO ANYONEPROPRIETARYCANNOT BE RESOLD$12$28
Industry TrendsBrand Founders6 min read

Same Factory, $28 Versus $12. The Question Is Whether You Paid for a Formula or Rented One.

Beauty Independent published a piece on 18 August examining whether products from the same contract manufacturer are really the same. Its useful distinction is not about factories at all: it is between brands that license a manufacturer's stock formula, which can be sold to anyone, and brands that pay for custom work the manufacturer is contractually barred from reselling. One of those is an asset you own. The other is a rental you are marking up, and the margin depends entirely on nobody looking too closely.

21 Aug 2026Read →
WHO READS THE LISTING FIRSTBLOCK THE AGENTSIZE / INCI / PRICESIZE / ? / PRICESIZE / INCI / PRICEAGENTCOMPARESSHORTLISTMISSING FIELD= NOT SHOWNREADABLE BEATS BEAUTIFUL
Industry TrendsBrand FoundersUS6 min read

A US Appeals Court Just Made AI Shopping Agents Unblockable. Your Product Page Is Now Read by Software First.

On 10 August the Ninth Circuit lifted the injunction Amazon had won against Perplexity's AI shopping agent, ruling Amazon was unlikely to succeed in its computer-fraud claim because it is the shopper, not Perplexity, who accesses the site through the tool. The practical effect is that a marketplace cannot block third-party AI agents from browsing and buying on a customer's behalf. That changes who reads your product page first, and what it needs to say.

11 Aug 2026Read →
CATEGORY SHELF, 2027£38ENTRY LADDER$4$18$39$6919 BRANDS, ONE FIXTURE
Industry TrendsBrand Founders5 min read

Sephora Just Named 19 Korean Brands Landing in 500 US Doors. The UK Version Arrives in 2027. Price Your Range Accordingly.

Sephora revealed the 19 Olive Young-curated Korean brands launching across 500-plus US stores and Sephora.com from 20 August, with skincare priced from $4 to $69. Expansion to Hong Kong, Singapore, Malaysia and Thailand follows later in 2026, and the UK, Middle East and Australia in 2027. For a UK skincare brand, this is eighteen months of notice about what the price architecture on your category shelf is going to look like.

6 Aug 2026Read →